TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties-Reference-Cited by-同舟云学术

TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties

Published:2011-08-23 Issue:2 Volume:26 Page:236-243
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Goh K C,Novotny-Diermayr V,Hart S,Ong L C,Loh Y K,Cheong A,Tan Y C,Hu C,Jayaraman R,William A D,Sun E T,Dymock B W,Ong K H,Ethirajulu K,Burrows F,Wood J M

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2011218.pdf

Reference27 articles.

1. Baker SJ, Reddy EP . Targeted inhibition of kinases in cancer therapy. Mt Sinai J Med 2010; 77: 573–586.

2. Negrier S, Raymond E . Antiangiogenic treatments and mechanisms of action in renal cell carcinoma. Invest New Drugs 2011, e-pub ahead of print, doi: 10.1007/s10637-10011-19677-10636.

3. Worns MA, Galle PR . Novel inhibitors in development for hepatocellular carcinoma. Expert Opin Investig Drugs 2010; 19: 615–629.

4. Knockaert M, Greengard P, Meijer L . Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci 2002; 23: 417–425.

5. Shapiro GI . Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 2006; 24: 1770–1783.

Cited by 112 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CDK9 inhibitors for the treatment of solid tumors;Biochemical Pharmacology;2024-11

2. Developments of Fms-like Tyrosine Kinase 3 Inhibitors as Anticancer Agents for AML Treatment;Current Medicinal Chemistry;2024-09

3. A review on macrocyclic kinase inhibitors in clinical trials;International Journal of Pharmaceutical Chemistry and Analysis;2024-07-15

4. Recent Discovery and Development of Inhibitors that Target CDK9 and Their Therapeutic Indications;Journal of Medicinal Chemistry;2024-04-02

5. Discovery of novel macrocyclic derivatives as potent and selective cyclin-dependent kinase 2 inhibitors;Bioorganic & Medicinal Chemistry;2024-04